Nello Mainolfi Sells 50,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 50,000 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at approximately $79,321,592. This trade represents a 6.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, July 1st, Nello Mainolfi sold 80,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $115.29, for a total transaction of $9,223,200.00.
• On Wednesday, April 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $81.18, for a total transaction of $2,435,400.00.

Kymera Therapeutics Stock Down 4.3%

KYMR opened at $114.16 on Thursday. Kymera Therapeutics, Inc. has a 52-week low of $36.65 and a 52-week high of $130.05. The company has a 50 day moving average of $89.15 and a two-hundred day moving average of $83.82. The company has a market cap of $9.39 billion, a P/E ratio of -31.98 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The business had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.82) EPS. Research analysts anticipate that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current year.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. Baker BROS. Advisors LP grew its stake in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after acquiring an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC boosted its holdings in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares during the last quarter. Vanguard Group Inc. grew its stake in Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Finally, State Street Corp increased its holdings in Kymera Therapeutics by 9.4% during the 4th quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after purchasing an additional 190,383 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have commented on KYMR. Brookline Capital Markets restated a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Canaccord Genuity Group increased their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a research note on Friday, June 26th. B. Riley Financial boosted their price target on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Morgan Stanley restated an “overweight” rating and issued a $119.00 price target on shares of Kymera Therapeutics in a report on Thursday, April 30th. Finally, Truist Financial increased their price objective on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $121.41.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.